iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma's arm Eugia Pharma gets USFDA nod for Triamcinolone Acetonide Injectable Suspension

6 Jul 2022 , 03:19 PM

Aurobindo Pharma Limited has announce that its wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/10 mL.

Triamcinolone Acetonide Injectable Suspension USP, 200 mg/5 mL (40 mg/mL) Multiple-dose vials and 400 mg/10 mL (40 mg/mL) Multiple-dose vials, to be bioequivalent and therapeutically equivalent to the RLD, Kenalog-40 Injectable Suspension, 40 mg/mL, of Bristol-Myers Squibb Company. The product is being launched this month. The approved product has an estimated market size of around US$ 73 million for the twelve months ending May 2022, according to IQVIA.

This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Triamcinolone Acetonide Injectable Suspension is in therapeutic Category of Synthetic glucocorticoid corticosteroid and indicated for the treatment of Intramuscular and Intra-Articular use:

  • Intramuscular – Where oral therapy is not feasible: allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases (palliative treatment), nervous system, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders
  • Intra-Articular – adjunctive therapy for short-term administration in: acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
At around 3:18 PM, Aurobindo Pharma was trading at Rs544.05 per share up by Rs10.75 or 2.02% from its previous closing of Rs533.30 per share on the BSE.

Related Tags

  • Aurobindo Pharma Ltd
  • Aurobindo Pharma Ltd shares
  • Aurobindo Pharma Ltd stocks
  • Bortezomib
  • Eugia Pharma
  • Injection
  • news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.